Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Emberton

Showing results (61-70 of 108) with videos related to

Pageof 11
Sort By:
BJU International|June 26, 2003
Diagnostic accuracy of flow rate testing in urologyH R H Patel, F Garcia-Montes, N Christopher, et al.
The Journal of Urology|November 13, 2004
Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasiaV Watson, M Ryan, C T Brown, et al.
The Journal of Urology|May 19, 2007
Re: Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. A. Villers, P. Puech, D. Mouton, X. Leroy, C. Ballereau and L. Lemaitre, J Urol 2006; 176: 2432-2437H U Ahmed, J Calleary, M Arya, et al.
The British Journal of Radiology|January 19, 2012
Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent diseaseS Punwani, M Emberton, M Walkden, et al.
Prostate Cancer and Prostatic Diseases|March 14, 2007
Point-of-care PSA testing: an evaluation of PSAwatchO Karim, A Rao, M Emberton, et al.
BJU International|March 5, 2003
The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened?C T Brown, E O'Flynn, J Van Der Meulen, et al.
Voprosy Onkologii|October 26, 2010
[Significance of the number of biopsy specimens from the prostate gland for adequate clinical appraisal of neoplasia]V V Iremashvili, A K Chepurov, M Emberton, et al.
World Journal of Urology|October 15, 2013
Role of focal salvage ablative therapy in localised radiorecurrent prostate cancerA Kanthabalan, M Arya, S Punwani, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 3, 2020
What to expect from a non-suspicious prostate MRI? A reviewG Fiard, J M Norris, T A Nguyen, et al.
The Journal of Urology|January 13, 2006
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once dailyR Hartung, H Matzkin, A Alcaraz, et al.
Pageof 11

Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
BJU International|June 26, 2003
Diagnostic accuracy of flow rate testing in urologyH R H Patel, F Garcia-Montes, N Christopher, et al.
The Journal of Urology|November 13, 2004
Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasiaV Watson, M Ryan, C T Brown, et al.
The Journal of Urology|May 19, 2007
Re: Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. A. Villers, P. Puech, D. Mouton, X. Leroy, C. Ballereau and L. Lemaitre, J Urol 2006; 176: 2432-2437H U Ahmed, J Calleary, M Arya, et al.
The British Journal of Radiology|January 19, 2012
Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent diseaseS Punwani, M Emberton, M Walkden, et al.
Prostate Cancer and Prostatic Diseases|March 14, 2007
Point-of-care PSA testing: an evaluation of PSAwatchO Karim, A Rao, M Emberton, et al.
BJU International|March 5, 2003
The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened?C T Brown, E O'Flynn, J Van Der Meulen, et al.
Voprosy Onkologii|October 26, 2010
[Significance of the number of biopsy specimens from the prostate gland for adequate clinical appraisal of neoplasia]V V Iremashvili, A K Chepurov, M Emberton, et al.
World Journal of Urology|October 15, 2013
Role of focal salvage ablative therapy in localised radiorecurrent prostate cancerA Kanthabalan, M Arya, S Punwani, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 3, 2020
What to expect from a non-suspicious prostate MRI? A reviewG Fiard, J M Norris, T A Nguyen, et al.
The Journal of Urology|January 13, 2006
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once dailyR Hartung, H Matzkin, A Alcaraz, et al.
Pageof 11